Werkgroep Cardiologische centra Nederland

BEST (Follow-up)

A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events
Medicine
bexagliflozin
Population
Diabetes mellitus
Phase
III
Starting year
2015
More information
ClinivalTrials.gov